Leerink analyst Jason Gerberry calls yesterday's post-earnings selloff in shares of Endo overdone. There is confusion around Xiaflex seasonality and investors read too much into accounting impairments taken on two Auxilium brands that are non-core to the story, Gerberry tells investors in a research note. When the dust settles from Valeant (VRX) related concerns, the valuation of Endo will be one of the most compelling in the group, the analyst contends. He lowered his price target for shares to $64 from $74 and keeps an Outperform rating on the name.